Metrohm and FOSS Enter Strategic Alliance - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Metrohm and FOSS Enter Strategic Alliance


Metrohm and FOSS have entered into a strategic alliance in which Metrohm will become the sole global distributor of FOSS NIR instruments for the chemical, petrochemical, pharmaceutical, and environmental sectors.

“Metrohm will extend its product offering beyond the company’s traditional focus on solutions for wet-chemistry analytical techniques thereby benefiting our customers with new possibilities both in laboratory and process analysis,” said Christoph Fässler, CEO of Metrohm in a company statement.

FOSS will continue its R&D program within NIR technology and manufacturing for both companies and will focus its NIR business on the food and agricultural industries, according to a joint company statement.

Under the deal, FOSS NIRSystems, Inc., based in Laurel, MD, USA, will become a division of Metrohm USA to be named Metrohm NIRSystems. The global NIR instrument business for these sectors will continue to be run by the Metrohm NIRSystems division of Metrohm USA.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy

Click here